Belgium-based biopharmaceutical firm Galapagos has begun the Phase I clinical trial of GLPG3067 for the treatment of patients with cystic fibrosis (CF).

The trial initiation has triggered a $7.5m milestone payment from the firm's collaboration partner AbbVie.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GLPG3067 is the third potentiator of Galapagos' CF drug candidates, being developed as part of the alliance between the firms to discover, develop and commercialise new therapies for the disease.

To be conducted in up to 48 healthy subjects, the randomised, double-blind, placebo controlled, single-centre trial will assess the safety and tolerability of oral GLPG0367 and GLPG3067 + GLPG2222 combination, as well as the pharmacokinetics of GLPG0367.

Galapagos chief scientific officer Dr Piet Wigerinck said: "We continue to explore additional molecules to enrich our growing portfolio of cystic fibrosis drug candidates.

See Also:

"We continue to explore additional molecules to enrich our growing portfolio of cystic fibrosis drug candidates."

"We plan to initiate multiple studies within our CF portfolio in the course of this year, as we get closer to our goal of initiating a patient evaluation of a triple combination therapy by mid-2017."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The first part of the trial will evaluate single ascending doses of GLPG3067, while the second part will include administration of multiple ascending doses of GLPG3067 for 14 days.

Galapagos and AbbVie are working towards addressing three complementary components of CF with a potential combination therapy.

Galapagos is currently evaluating potentiator GLPG2451 and corrector GLPG2222 in healthy participants.

The firms intend to further add corrector GLPG2737 for a triple combination therapy that will be initially assessed in healthy volunteers and later in patients with the F508del mutation.